Licensing Opportunity – Next-Generation CAR-T for Multiple Myeloma
This enhanced BCMA-targeting CAR-T technology co-expresses a granzyme B–NOXA fusion protein, overcoming resistance in multiple myeloma by directly neutralizing MCL-1–mediated survival mechanisms.
Improved tumor killing in vitro & in vivo
Selective targeting of malignant cells
Compatible with current CAR-T platforms, including in vivo engineering strategies
Read the publication in Nature Communications:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089368/
Patent application upon request
We are actively seeking industry partners for licensing and development.
Contact Danielle Counotte to explore this opportunity.
Utrecht Holdings is the Utrecht University and UMC Utrecht in-house partner for knowledge transfer and start-ups.
Menu
Visiting address
Contact Us
T: 085 – 087 63 69
BTW-nummers (VAT numbers): UU Holding BV: NL806771604B01 || UMCU Holding BV: NL806125214B01